A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation

Transplantation

Volumn 63, Issue 7, 1997, Pages 977-983

  Pirsch, John D ^a   Miller, Joshua ^b   Deierhoi, Mark H ^b   Vincenti, Flavio ^b   Filo, Ronald S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; TACROLIMUS;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREMOR;

ACUTE DISEASE; ADULT; ANTILYMPHOCYTE SERUM; CADAVER; CAUSE OF DEATH; CLINICAL PROTOCOLS; CREATININE; CROSS-OVER STUDIES; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; KIDNEY TRANSPLANTATION; MALE; PATIENT SELECTION; REGRESSION ANALYSIS; TACROLIMUS;

EID: 0031001622     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199704150-00013     Document Type: Article

References (32)

1. Goto T, Kino T, Hatanaka M, et al. FK506: historical perspectives. Transplant Proc 1991; 23: 2713.
2. US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
3. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
4. Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine. Transplant Proc 1991; 23: 2977.
5. Takaya S, Bronsther O, Todo S, et al. Retransplantation of liver: a comparison of FK506- and cyclosporine-treated patients. Transplant Proc 1991; 23: 3026.
6. Tzakis AG, Reyes J, Todo S, et al. FK506 versus cyclosporine in pediatric liver transplantation. Transplant Proc 1991; 23: 3010.
7. Shapiro R, Jordan M, Scantlebury V, et al. FK506 in clinical kidney transplantation. Transplant Proc 1991; 23: 3065.
8. Japanese FK506 Study Group. Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK506. Transplant Proc 1991; 23: 3111.
9. Japanese FK506 Study Group. Japanese study of FK506 on kidney transplantation: results of an early phase II study. Transplant Proc 1991; 23: 3071.
10. Japanese FK506 Study Group. Japanese study of FK506 on kidney transplantation: results of late phase II study. Transplant Proc 1993; 25: 649.
11. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506/prednisone vs FK506/azathioprine/ prednisone in renal transplant patients. Transplant Proc 1995; 27: 814.
12. Schleibner S, Krauss M, Wagner K, et al. FK506 versus cyclosporine in the prevention of renal allograft rejection - European pilot study: six-week results. Transplant Int 1995; 8: 86.
13. Laskow DA, Vincenti F, Neylan J, et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. Transplant Proc 1995; 27: 809.
14. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 45: 411
15. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
16. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early vs late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
17. Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8: 328.
18. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995; 60: 1384.
19. Häyry P. Chronic allograft rejection: an update. Clin Transplant 1994; 8: 160.
20. Matas AJ. Chronic rejection: definitions and correlates. Clin Transplant 1994; 8: 162.
21. Hirano Y, Fujihara S, Ohara K, et al. Morphological and functional changes in islets of Langerhans in FK506-treated rats. Transplantation 1992; 53: 889.
22. Tze WJ, Tai J, Murase N, et al. Effect of FK506 on glucose metabolism and insulin secretion in rats. Transplant Proc 1991; 23: 3158.
23. Ericzson BG, Wijnen RMH, Kobota K, et al. FK506-induced impairment of glucose metabolism in the primate: studies in pancreatic transplant recipients and in non-transplanted animals. Transplantation 1992; 54: 615.
24. Carroll PB, Boschero AC, Li MY, et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat Islets of Langerhans. Transplantation 1991; 51: 275.
25. Jordan ML, Shapiro R, Vivas CA, et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860.
26. Scantlebury V, Shapiro R, Fung J, et al. New onset diabetes in FK506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23: 3169.
27. Shapiro R, Jordan M, Fung J, et al. Kidney transplantation under FK506 immunosuppression. Transplant Proc 1991; 23: 920.
28. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506/prednisone vs FK506/azathioprine/ prednisone in renal transplant patients. Transplant Proc 1995; 27: 814.
29. Yamamoto H, Akazawa S, Yamaguchi Y, et al. Effects of cyclosporine A and low dosages of steroids on posttransplantation diabetes in kidney transplant recipients. Diabetes Care 1991; 14: 867.
30. Von Kiparski A, Frei D, Uhlschmid G, et al. Post-transplant diabetes mellitus in renal allograft recipients: a matched pair control study. Nephrol Dial Transplant 1990; 5: 220.
31. Krentz AJ, Dmitrewski J, Mayer D, Nattrass M. Effects of immunosuppressive agents on glucose metabolism: implication for the development of post-transplant diabetes mellitus. Clin Immunother 1995; 4: 103.
32. Dimeny E, Fellstrom B, Larsson E, et al. The role of lipoprotein abnormalities in chronic vascular rejection after kidney transplantation. Transplant Proc 1995; 27: 2036.